Chandigarh, May 02: In a defining moment for global oncology collaboration, the Fortis Cancer Institute is all set to host Fortis Cancer Summit 2026, a landmark international conference on 2nd – 3rd May 2026 at Hotel Andaz, New Delhi, bringing together leading minds in oncology alongwith cancer research experts from India and across the world, to collectively shape the future of cancer care.
The summit will bring together over 50 Premier Cancer Centers across India, along with 500+ National Faculty and 100+ International faculty representing 25 countries, creating one of the most influential global platforms for oncology dialogue and exchange of best practices. With participation from over 1200 Delegates and 150 oncology students, the national capital will emerge as a Global Oncology Village fostering scientific exchange, innovation and collaboration in cancer care. Uniting global and Indian oncology leaders to advance borderless, future-ready cancer care.
At a time, when cancer treatment guidelines vary across geographies, the conference will be built around a powerful and forward-looking theme, ‘Beyond Evidence-Based Oncology’ emphasizing the translation of evolving evidence into real-world clinical practice. Spread over two days, the summit will feature 25+ Thematic Sessions, ranging from organ-specific oncology sessions to multidisciplinary discussions and hands-on workshops, each designed to deliver practical insights, evolving evidence, and real-world applications across cancer care.
The summit will feature renowned global experts across multiple oncology disciplines, including pioneers in Proton therapy, MR – guided radiotherapy (MR Linac), radiation oncology, medical oncology, surgical oncology, hematology, pediatric hematology, gynae oncology and genomics reinforcing its focus on integrated, next-generation cancer care.
An eminent line-up of national and global experts will be part of the summit including Dr Niti Krishna Raizada – Principal Director, Medical and Haemato Oncology, Fortis Bengaluru, Dr Boman Dhabar – Director, Medical Oncology, Fortis Mulund, Dr Mohan Keshavmurthy – Principal Director, Urology, Fortis Bengaluru, Dr G K Rath, one of India’s most distinguished radiation oncologists, Dr Ramesh Sarin, Surgical Oncologist, Apollo Hospitals, Dr Rana Patir – Chairman, Neurosurgery, Fortis Gurugram, Prof Sudeep Gupta, Director, Tata Memorial Hospital, Dr Nitesh Rohatgi and Dr Ankur Bahl Principal Director, Medical Oncology, Fortis Gurugram, Dr Suman S. Karanth, Additional Director, Medical Oncology, Fortis Gurugram, Dr Sandeep Vaishya, Executive Director & HOD Neuro Surgery, Fortis Gurugram, Dr Rahul Bhargava, Principal Director and Chief Haematology, Fortis Gurugram, Dr Rama Joshi, Chairman-Gynae Oncology and Robotic Surgery, Fortis Gurugram, Dr Vedant Kabra, Principal Director-Surgical Oncology, Fortis Gugugram.
The global faculty includes Dr Bassim Al Bahraini, Sr Consultant, Medical Oncology, Royal Hospital, Oman and Vice Chairman, Treatment Abroad, MOH, Oman,Iliya Karniliyus Salu, Chief Medical Director, Trust Charitos Hospital Abuja, Nigeria, Asamutdinov Jaloliddin, Director, State Institution, Center for Licensing and Accreditation of Medical Organizations, Uzbekistan, Dr. Mary McCormack, Consultant Clinical Oncologist at University College London Hospital, Dr Peter Fasching from Germany, Dr Peter Lim from USA amongst others, thus bringing together diverse global expertise to enrich clinical dialogue and collaboration.
Iliya Karniliyus Salu, Chief Medical Director, Trust Charitos Hospital Abuja, Nigeria said,
“Cancer care today demands stronger global collaboration than ever before, as the challenges we face are increasingly complex and universal. Platforms like the Fortis Cancer Summit are critical in bringing together diverse clinical experiences, research advancements, and technological innovations from across geographies. The theme ‘Beyond Evidence-Based Oncology’ is particularly relevant, as the future of cancer care lies not only in evidence, but in translating that evidence into personalised, multidisciplinary, and patient-centric treatment approaches. I look forward to meaningful discussions and knowledge exchange that can help shape more effective and accessible cancer care pathways worldwide.”
Dr Nitesh Rohatgi, Principal Director, Medical Oncology, Fortis Memorial Research Institute, Gurugram said,
“The future of cancer care lies in collaboration, innovation, and the ability to adapt evidence into personalized patient care pathways. Through the Fortis Cancer Summit, we are creating an ecosystem where clinicians, researchers, and young oncology professionals can exchange insights, challenge conventional approaches, and explore the next frontier of cancer management. This summit is not just about knowledge-sharing; it is about building a stronger, globally aligned oncology community committed to transforming patient outcomes.”
Dr Ankur Bahl, Principal Director, Medical Oncology, Fortis Memorial Research Institute, Gurugram said,
“Oncology is at a transformative juncture where scientific innovation, precision medicine, and multidisciplinary care are redefining treatment outcomes. The Fortis Cancer Summit is designed as a platform to bridge the gap between emerging evidence and its real-world clinical application. By bringing together some of the finest oncology minds from across the globe, we aim to foster meaningful dialogue around advancing standards of care, improving access to cutting-edge therapies, and strengthening collaborative approaches that ultimately translate into better survival and quality of life for patients.”
Dr Ritu Garg, Chief Growth and Innovation Officer, Fortis Healthcare, said,
“It’s a proud moment for Fortis Healthcare to host the 2nd Edition of Fortis Cancer Summit, reflecting Fortis Cancer Institute’s commitment to advancing cancer care through technology, science, empathy, and innovation. As oncology continues to evolve rapidly, this summit positions India and Fortis at the forefront of shaping a unified, patient-centric global cancer care ecosystem. The insights generated here are expected to directly influence clinical practices, ultimately improving patient outcomes and survival rates.”
